

Craig A Harrison

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7688316/publications.pdf>

Version: 2024-02-01

52
papers

2,351
citations

201674

27
h-index

214800

47
g-index

52
all docs

52
docs citations

52
times ranked

3320
citing authors

#	ARTICLE	IF	CITATIONS
1	Human INHBB Gene Variant (c.1079T>C;p.Met360Thr) Alters Testis Germ Cell Content, but Does Not Impact Fertility in Mice. <i>Endocrinology</i> , 2022, 163, .	2.8	2
2	Effect of cumulin and super-GDF9 in standard and biphasic mouse IVM. <i>Journal of Assisted Reproduction and Genetics</i> , 2022, 39, 127-140.	2.5	8
3	Inhibin Inactivation in Female Mice Leads to Elevated FSH Levels, Ovarian Overstimulation, and Pregnancy Loss. <i>Endocrinology</i> , 2022, 163, .	2.8	5
4	Potential treatment of keloid pathogenesis with follistatin 288 by blocking the activin molecular pathway. <i>Experimental Dermatology</i> , 2021, 30, 402-408.	2.9	9
5	Structure of AMH bound to AMHR2 provides insight into a unique signaling pair in the TGF- β family. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	26
6	TGFBR3L is an inhibin B co-receptor that regulates female fertility. <i>Science Advances</i> , 2021, 7, eabl4391.	10.3	21
7	TMEPAI/PMEP1 Is a Positive Regulator of Skeletal Muscle Mass. <i>Frontiers in Physiology</i> , 2020, 11, 560225.	2.8	5
8	Engineering the Ovarian Hormones Inhibin A and Inhibin B to Enhance Synthesis and Activity. <i>Endocrinology</i> , 2020, 161, .	2.8	8
9	A variant of human growth differentiation factor-9 that improves oocyte developmental competence. <i>Journal of Biological Chemistry</i> , 2020, 295, 7981-7991.	3.4	28
10	Activin A-Induced Cachectic Wasting Is Attenuated by Systemic Delivery of Its Cognate Propeptide in Male Mice. <i>Endocrinology</i> , 2019, 160, 2417-2426.	2.8	17
11	Serum Concentrations of Oocyte-Secreted Factors BMP15 and GDF9 During IVF and in Women With Reproductive Pathologies. <i>Endocrinology</i> , 2019, 160, 2298-2313.	2.8	19
12	Inhibin: To Betaglycan, or Not to Betaglycan. <i>Endocrinology</i> , 2019, 160, 341-342.	2.8	1
13	Functional Characterization of Two New Variants in the Bone Morphogenetic Protein 7 Prodomain in Two Pairs of Monozygotic Twins With Hypospadias. <i>Journal of the Endocrine Society</i> , 2019, 3, 814-824.	0.2	2
14	Cumulin and FSH Cooperate to Regulate Inhibin B and Activin B Production by Human Granulosa-Lutein Cells In Vitro. <i>Endocrinology</i> , 2019, 160, 853-862.	2.8	17
15	Molecular characterization of latent GDF8 reveals mechanisms of activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E866-E875.	7.1	30
16	Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	32
17	Structural basis for potency differences between GDF8 and GDF11. <i>BMC Biology</i> , 2017, 15, 19.	3.8	90
18	Multiple Soluble TGF- β Receptors in Addition to Soluble Endoglin Are Elevated in Preeclamptic Serum and They Synergistically Inhibit TGF- β Signaling. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3065-3074.	3.6	13

#	ARTICLE	IF	CITATIONS
19	Specific targeting of TGF- β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E5266-E5275.	7.1	90
20	The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget, 2017, 8, 18640-18656.	1.8	66
21	Targeting TGF- β Mediated SMAD Signaling for the Prevention of Fibrosis. Frontiers in Pharmacology, 2017, 8, 461.	3.5	393
22	BMP15 Mutations Associated With Primary Ovarian Insufficiency Reduce Expression, Activity, or Synergy With GDF9. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1009-1019.	3.6	31
23	A Novel, More Efficient Approach to Generate Bioactive Inhibins. Endocrinology, 2016, 157, 2799-2809.	2.8	10
24	Selection of internal control genes for analysis of gene expression in normal and diseased human dermal fibroblasts using quantitative real-time PCR. Experimental Dermatology, 2016, 25, 911-914.	2.9	3
25	Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice. Science Translational Medicine, 2016, 8, 348ra98.	12.4	70
26	Differential Effects of IL6 and Activin A in the Development of Cancer-Associated Cachexia. Cancer Research, 2016, 76, 5372-5382.	0.9	62
27	The TGF- β Signalling Network in Muscle Development, Adaptation and Disease. Advances in Experimental Medicine and Biology, 2016, 900, 97-131.	1.6	56
28	Biological activity and in vivo half-life of pro-activin A in male rats. Molecular and Cellular Endocrinology, 2016, 422, 84-92.	3.2	14
29	Cumulin, an Oocyte-secreted Heterodimer of the Transforming Growth Factor- β Family, Is a Potent Activator of Granulosa Cells and Improves Oocyte Quality. Journal of Biological Chemistry, 2015, 290, 24007-24020.	3.4	130
30	Inhibin Biosynthesis and Activity Are Limited by a Prodomain-Derived Peptide. Endocrinology, 2015, 156, 3047-3057.	2.8	10
31	Development of Novel Activin-Targeted Therapeutics. Molecular Therapy, 2015, 23, 434-444.	8.2	46
32	Aberrant GDF9 Expression and Activation Are Associated With Common Human Ovarian Disorders. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E615-E624.	3.6	29
33	Readiness to Change and Reasons for Intended Reduction of Alcohol Consumption in Emergency Department versus Trauma Population. Western Journal of Emergency Medicine, 2014, 15, 337-344.	1.1	6
34	Use of detergent-based buffers allows detection of precursor inhibin forms in an immunoassay format. Molecular and Cellular Endocrinology, 2013, 381, 106-114.	3.2	6
35	Species Differences in the Expression and Activity of Bone Morphogenetic Protein 15. Endocrinology, 2013, 154, 888-899.	2.8	28
36	Activation of Latent Human GDF9 by a Single Residue Change (Gly391Arg) in the Mature Domain. Endocrinology, 2012, 153, 1301-1310.	2.8	40

#	ARTICLE	IF	CITATIONS
37	New insights into the mechanisms of activin action and inhibition. <i>Molecular and Cellular Endocrinology</i> , 2012, 359, 2-12.	3.2	81
38	Prodomains regulate the synthesis, extracellular localisation and activity of TGF- β superfamily ligands. <i>Growth Factors</i> , 2011, 29, 174-186.	1.7	99
39	Extra-ovarian expression and activity of growth differentiation factor 9. <i>Journal of Endocrinology</i> , 2009, 202, 419-430.	2.6	16
40	Inhibin B Is a More Potent Suppressor of Rat Follicle-Stimulating Hormone Release than Inhibin A in Vitro and in Vivo. <i>Endocrinology</i> , 2009, 150, 4784-4793.	2.8	38
41	A Common Biosynthetic Pathway Governs the Dimerization and Secretion of Inhibin and Related Transforming Growth Factor β (TGF β) Ligands. <i>Journal of Biological Chemistry</i> , 2009, 284, 9311-9320.	3.4	63
42	Suppression of Inhibin A Biological Activity by Alterations in the Binding Site for Betaglycan. <i>Journal of Biological Chemistry</i> , 2008, 283, 16743-16751.	3.4	42
43	Interleukin 11 and Activin A Synergise to Enhance Medroxyprogesterone But Not cAMP-Induced Decidualization of Human Endometrial Stromal Cells.. <i>Biology of Reproduction</i> , 2008, 78, 143-143.	2.7	5
44	Inhibin A and B in Vitro Bioactivities Are Modified by Their Degree of Glycosylation and Their Affinities to Betaglycan. <i>Endocrinology</i> , 2007, 148, 2309-2316.	2.8	47
45	Activin-A Binds Follistatin and Type II Receptors through Overlapping Binding Sites: Generation of Mutants with Isolated Binding Activities. <i>Endocrinology</i> , 2006, 147, 2744-2753.	2.8	25
46	Identification of Distinct Inhibin and Transforming Growth Factor β -binding Sites on Betaglycan. <i>Journal of Biological Chemistry</i> , 2006, 281, 17011-17022.	3.4	71
47	Antagonists of activin signaling: mechanisms and potential biological applications. <i>Trends in Endocrinology and Metabolism</i> , 2005, 16, 73-78.	7.1	188
48	An Activin Mutant with Disrupted ALK4 Binding Blocks Signaling via Type II Receptors. <i>Journal of Biological Chemistry</i> , 2004, 279, 28036-28044.	3.4	63
49	Activins and Inhibins and Their Signaling. <i>Annals of the New York Academy of Sciences</i> , 2004, 1038, 142-147.	3.8	71
50	Identification of a Functional Binding Site for Activin on the Type I Receptor ALK4. <i>Journal of Biological Chemistry</i> , 2003, 278, 21129-21135.	3.4	49
51	Inhibin binding sites and proteins in pituitary, gonadal, adrenal and bone cells. <i>Molecular and Cellular Endocrinology</i> , 2001, 180, 63-71.	3.2	34
52	Identification of Specific Inhibin A-Binding Proteins on Mouse Leydig (TM3) and Sertoli (TM4) Cell Lines*. <i>Endocrinology</i> , 2001, 142, 1393-1402.	2.8	36